SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: erickerickson who wrote (62913)11/19/2024 11:34:58 AM
From: plhky34653 Recommendations

Recommended By
jhcimmu
Olecranon
sysiphus

   of 63305
 
SAVA maximizing strategy...
----------------
What do people here feel would be a shareholder maximizing strategy for a product launch:

a) Partner with an existing global sales force

b) Build out an organic sales force

c) Sell the company to large bio

I would prefer option a or c -- preferably c.

IMMU sold for 21 billion. SAVA could sell for much more -- the revenue this drug could generate is HUGE!!!!!

SAVA's mkt cap right now is 1.3 billion.
If it was bought outright for 21 bil the share price would be around $450

If bought for 50 bil then share price goes to about $1075

I'm all about option C if SAVA gets really good ph 3 results.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News